Hepatocellular carcinoma: from bedside to proteomics.

Area of Science:

• Oncology
• Hepatology
• Proteomics

Background:

• Hepatocellular carcinoma (HCC) is the most common primary liver cancer, causing ~1 million deaths annually, primarily in developing nations.
• Key etiological factors include hepatitis B/C virus infections and aflatoxin exposure.
• Current challenges in HCC management include late diagnosis and limited curative treatment options.

Purpose of the Study:

• To identify novel diagnostic markers for early HCC detection.
• To discover tumor-specific proteins as potential therapeutic targets for HCC treatment.
• To advance understanding of HCC pathogenesis and progression through proteomic analysis.

Main Methods:

• Proteomics was employed for global analysis of protein expression in HCC.
• In vitro systems, including multiple hepatoma cell lines (HepG2, Huh7, SK-Hep1, Hep3B) and normal liver/non-transformed cell lines, were used for proteome profiling.
• A protein database was created for the HCC-M cell line.

Main Results:

• Comparative proteome analyses identified distinct protein expression profiles between HCC cell lines and normal liver/non-transformed cells.
• Established proteomic methodologies for analyzing HCC-related proteins.
• Initiated proteomic analysis of hepatic stellate cells to understand their role in liver fibrosis.

Conclusions:

• Proteomics is a key technology facilitating the discovery of diagnostic markers and therapeutic targets for HCC.
• Future proteomic analyses will utilize tumor tissues for more accurate pathological representation.
• Understanding protein expression in hepatic stellate cells is crucial for targeting liver fibrosis progression.